Grants and Contributions

• CIHR-IG will provide funding for applications that are determined to be relevant to its mandate:
o The Institute of Genetics (IG) supports research on the human and model genomes and on all aspects of genetics, basic biochemistry and cell biology related to health and disease, including the translation of knowledge into health policy and practice, and the societal implications of genetic discoveries

• CIHR-IG will provide funding for applications that are determined to be relevant to its mandate:
o The Institute of Genetics (IG) supports research on the human and model genomes and on all aspects of genetics, basic biochemistry and cell biology related to health and disease, including the translation of knowledge into health policy and practice, and the societal implications of genetic discoveries

• CIHR-IG will provide funding for applications that are determined to be relevant to its mandate:
o The Institute of Genetics (IG) supports research on the human and model genomes and on all aspects of genetics, basic biochemistry and cell biology related to health and disease, including the translation of knowledge into health policy and practice, and the societal implications of genetic discoveries

This priority announcement will provide funding for applications to support research on decision making when it comes to policies, programs and practices related to cancer care (including screening and prevention) in the following research areas:
o Health Economics and Health Services Research in Cancer Control

• The CIHR HIV/AIDS and STBBI Research Initiative (RI), under the leadership of the CIHR Institute of Infection and Immunity (III), is responsible for the funding, management and oversight of research with a primary focus on HIV/AIDS and/or other STBBI (as identified in the Public Health Agency of Canada's Pan-Canadian STBBI Framework for Action). This includes, but is not limited to: human immunodeficiency virus (HIV), hepatitis B (HBV) and C (HCV), chlamydia, gonorrhea, syphilis, and human papilloma virus (HPV). This funding is provided across all CIHR Research Themes: biomedical research, clinical research, health services research and social, cultural, environmental and population health research.
• Research that focuses on key populations identified by Canada's Pan-Canadian STBBI Framework for Action is highly encouraged.
• This priority announcement will fund one (1) early career investigator for a total of three (3) years.
• In alignment with CIHR’s commitment to equity, diversity and inclusion (EDI) in the research system, the RI champions EDI as a means to support excellence in research, training and knowledge mobilization. Therefore, we encourage people from diverse backgrounds, including groups underrepresented in science such as women and racial and ethnic minorities, to apply.

.
• Bridge funding can be used at the NPAs discretion to catalyze work on their proposed project in the manner they feel best moves forward their research program, for example, collection of pilot data, demonstration of feasibility, or work to address peer review comments.

• The CIHR Institute of Infection and Immunity (CIHR-III) will fund applications that are determined to be specifically relevant to their mandate with a primary focus on biomedical research in which the objective and aims are directed towards building foundational knowledge in immunology and/or infectious diseases. This priority announcement will prioritize funding for research in the following research areas:
o Infection:
¿ Zoonotic or vector-borne transmission of pathogens in the context of Global Climate Change;
¿ Understanding functional genomics and/or molecular epidemiology of emerging/re-emerging pathogens;
¿ Resistance to fungal infections and/or the role of bacteriophages in combatting antimicrobial resistance (AMR).
o Immunity:
¿ Immune mechanisms involved in the development of trained innate immunity;
¿ Immune mechanisms involved in the development and maintenance of tissue-specific immunity;
¿ Metabolic regulation of immune cells and processes (immunometabolism).
• Should there be no eligible applications relevant to the research areas identified above, III will fund applications that are relevant to its mandate with a primary focus on biomedical research in which the objective and aims are directed towards building foundational knowledge in immunology and/or infectious diseases.

• The CIHR Institute of Musculoskeletal Health and Arthritis (CIHR-IMHA) will fund applications that are determined to be relevant to its mandate and research priority areas as described below:
o IMHA Mandate:
¿ IMHA is mandated to provide research leadership related to: active living, mobility and the wide range of conditions related to bones, joints, muscles, connective tissue, skin as well as the mouth, teeth and craniofacial region.
o Research Priority Areas:
¿ Myalgic Encephalomyelitis (ME)
¿ Pain
¿ Oral Health

• The CIHR Institute of Musculoskeletal Health and Arthritis (CIHR-IMHA) will fund applications that are determined to be relevant to its mandate and research priority areas as described below:
o IMHA Mandate:
¿ IMHA is mandated to provide research leadership related to: active living, mobility and the wide range of conditions related to bones, joints, muscles, connective tissue, skin as well as the mouth, teeth and craniofacial region.
o Research Priority Areas:
¿ Myalgic Encephalomyelitis (ME)
¿ Pain
¿ Oral Health

• The CIHR Institute of Neurosciences, Mental Health and Addiction (CIHR-INMHA) will fund an application that is determined to be relevant to their mandate and research priority areas.